Company intelligence / Profile preview

Pliant Therapeutics

South San Francisco, California, United Statespliantrx.com ↗

Ownership: Public · PLRX
Development stage: Phase 2

Overview

Pliant recently discontinued its Phase 2b/3 BEACON-IPF trial of bexotegrast due to safety concerns, despite showing promising efficacy data regarding forced vital capacity (FVC). The company is now considering future dose-ranging Phase 2b studies with lower bexotegrast doses in pulmonary fibrosis and potentially other non-respiratory indications. The company announced a strategic realignment of its workforce on May 1, 2025, cutting 45% of staff.[7][9]

Therapeutic areas: GastroenterologyPulmonologyOncologyRare DiseasesNeurology
Modalities: Small moleculesmonoclonal antibodies
Industry: Biotech

Drug pipeline

13 assets

bexotegrast

12 more assets in the full pipeline.

Request access →

Financials

Market cap: $71.2M
Total revenue: $0
Enterprise value: $-58.1M

Beyond the preview

Go deeper on Pliant Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pliant Therapeutics.

Explore the full profile